Growth of meibomian glands post-MGP
| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O |
| Case | Lid | Atrophy grade | Post-MGP follow-up (months) | Glands analysed (n) | Pre-MGP total glandular area: ([total gland area / TMF] × 100) (%) | Post-MGP total glandular area: ([total gland area / TMF] × 100) (%) | Percentage point difference: (G–F) | % Growth in total gland area (per lid): (H / F) × 100 | Pre-MGP mean individual gland area: ([mean individual gland Area / TMF] × 100) (%) | Post-MGP mean individual gland area: ([mean individual gland area / TMF] × 100) (%) | Percentage point difference: (K–J) | % Growth in mean individual gland area: (L / J) × 100 | p Value (individual gland area post-MGP vs pre-MGP comparison) | Type(s) of growth seen on at least one MG/lid, within the TMF, using IR-M |
| Follow-up at ≤12 months | ||||||||||||||
| 004 | LU | 2 | 11.5 | 13 | 31.74 | 35.65 | 3.91 | 12.32 | 2.44 | 2.74 | 0.30 | 12.30 | 0.1637 | Increased density |
| 007 | RU | 2 | 8.5 | 13 | 29.41 | 29.80 | 0.39 | 1.33 | 2.26 | 2.29 | 0.03 | 1.33 | 0.8523 | Increased density and proximal lengthening |
| 007 (3) | LU | 3 | 8.5 | 15 | 21.37 | 25.78 | 4.41 | 20.61 | 1.42 | 1.72 | 0.30 | 21.13 | 0.0277 | Increased density, proximal lengthening, and new gland tissue |
| 011 | RU | 1 | 5.3 | 10 | 41.22 | 36.41 | −4.81 | −11.67 | 4.12 | 3.64 | −0.48 | −11.65 | 0.0975 | Proximal lengthening |
| 013 | RU | 1 | 5.8 | 9 | 40.52 | 39.21 | −1.31 | −3.23 | 4.50 | 4.36 | −0.14 | −3.11 | 0.4507 | Increased density |
| 016 | RU | 2 | 4.5 | 12 | 36.50 | 35.57 | −0.93 | −2.55 | 3.04 | 2.97 | −0.07 | −2.30 | 0.7250 | Increased density/stoutness |
| 018 | RU | 1 | 6.9 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | Increased density |
| 020 | RU | 2 | 7.0 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | Increased density |
| 022 | LU | 1 | 4.6 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | Increased density |
| 024 | RU | 2 | 5.3 | 12 | 40.31 | 48.06 | 7.75 | 19.23 | 3.36 | 4.01 | 0.65 | 19.35 | <0.0001 | Lengthening |
| 025 | RU | 1 | 7.6 | 12 | 47.98 | 48.50 | 0.52 | 1.08 | 4.00 | 4.04 | 0.04 | 1.00 | 0.8651 | Distal and proximal lengthening |
| 027 (2) | RU | 2 | 11.3 | 9 | 26.62 | 30.53 | 3.91 | 14.69 | 2.96 | 3.39 | 0.43 | 14.53 | 0.0345 | Increased density and proximal lengthening |
| 029 | RU | 3 | 7.1 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | Increased density |
| 034 | LU | 1 | 5.1 | 11 | 41.12 | 45.52 | 4.4 | 10.70 | 3.74 | 4.14 | 0.40 | 10.70 | 0.0292 | Discontinuous -> continuous |
| All lids ≤12 months | NA | NA | NA | 116 | 35.68 | 37.50 | 1.82 | 5.10 | 3.08 | 3.23 | 0.15 | 4.87 | 0.0145 | |
| Follow-up at >12 months | ||||||||||||||
| 003 | RU | 1 | 20.5 | 11 | 31.21 | 30.82 | −0.39 | −1.25 | 2.84 | 2.80 | −0.04 | −1.41 | 0.8029 | Discontinuous -> continuous |
| 026 | LU | 1 | 12.5 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | Discontinuous -> continuous |
| 032 (1) | RU | 1 | 24.9 | 11 | 32.48 | 38.96 | 6.47 | 19.93 | 2.95 | 3.54 | 0.59 | 20.00 | 0.0001 | Proximal lengthening |
| 032 | LU | 1 | 24.9 | 11 | 33.62 | 38.33 | 4.71 | 14.01 | 3.06 | 3.48 | 0.42 | 13.73 | 0.0097 | Proximal lengthening |
| All lids >12 months | NA | NA | NA | 33 | 32.44 | 36.04 | 3.6 | 11.10 | 2.95 | 3.28 | 0.31 | 11.19 | 0.0004 | |
| All follow-ups (4.5–25 months) | ||||||||||||||
| Total | NA | NA | NA | 149 | 34.93 | 37.16 | 2.23 | 6.38* | 3.05 | 3.24 | 0.19 | 6.23 | 0.0003 | |
(1)–(3): Lids represented in case studies and in figures 2–4.
*p=0.0447.
IR-M, infrared meibography; LU, left upper lid; MG, meibomian gland; MGP, meibomian gland probing; NA, not applicable/image not sufficient for quantitative analysis; RU, right upper lid; TMF, total measurement field. Discontinuous → Continuous indicates restoration of a continuous gland from discontinuous segments.